Biblio
Export 2446 results:
Author Title [ Type] Year Filters: First Letter Of Keyword is A [Clear All Filters]
“Analysis of the MIRIAD Data Shows Sex Differences in Hippocampal Atrophy Progression.”, J Alzheimers Dis, vol. 50, no. 3, pp. 847-57, 2016.
, “Anemia and Mild Cognitive Impairment in the German General Population.”, J Alzheimers Dis, vol. 49, no. 4, pp. 1031-42, 2016.
, “Anemia and Mild Cognitive Impairment in the German General Population.”, J Alzheimers Dis, vol. 49, no. 4, pp. 1031-42, 2016.
, “Anemia and Mild Cognitive Impairment in the German General Population.”, J Alzheimers Dis, vol. 49, no. 4, pp. 1031-42, 2016.
, “ANMerge: A Comprehensive and Accessible Alzheimer's Disease Patient-Level Dataset.”, J Alzheimers Dis, vol. 79, no. 1, pp. 423-431, 2021.
, “ANMerge: A Comprehensive and Accessible Alzheimer's Disease Patient-Level Dataset.”, J Alzheimers Dis, vol. 79, no. 1, pp. 423-431, 2021.
, “ANMerge: A Comprehensive and Accessible Alzheimer's Disease Patient-Level Dataset.”, J Alzheimers Dis, vol. 79, no. 1, pp. 423-431, 2021.
, “Antemortem-Postmortem Correlation of Florbetapir (18F) PET Amyloid Imaging with Quantitative Biochemical Measures of Aβ42 but not Aβ40.”, J Alzheimers Dis, vol. 61, no. 4, pp. 1509-1516, 2018.
, “Antemortem-Postmortem Correlation of Florbetapir (18F) PET Amyloid Imaging with Quantitative Biochemical Measures of Aβ42 but not Aβ40.”, J Alzheimers Dis, vol. 61, no. 4, pp. 1509-1516, 2018.
, “Antemortem-Postmortem Correlation of Florbetapir (18F) PET Amyloid Imaging with Quantitative Biochemical Measures of Aβ42 but not Aβ40.”, J Alzheimers Dis, vol. 61, no. 4, pp. 1509-1516, 2018.
, “Antemortem-Postmortem Correlation of Florbetapir (18F) PET Amyloid Imaging with Quantitative Biochemical Measures of Aβ42 but not Aβ40.”, J Alzheimers Dis, vol. 61, no. 4, pp. 1509-1516, 2018.
, “Antemortem-Postmortem Correlation of Florbetapir (18F) PET Amyloid Imaging with Quantitative Biochemical Measures of Aβ42 but not Aβ40.”, J Alzheimers Dis, vol. 61, no. 4, pp. 1509-1516, 2018.
, “Antemortem-Postmortem Correlation of Florbetapir (18F) PET Amyloid Imaging with Quantitative Biochemical Measures of Aβ42 but not Aβ40.”, J Alzheimers Dis, vol. 61, no. 4, pp. 1509-1516, 2018.
, “Antemortem-Postmortem Correlation of Florbetapir (18F) PET Amyloid Imaging with Quantitative Biochemical Measures of Aβ42 but not Aβ40.”, J Alzheimers Dis, vol. 61, no. 4, pp. 1509-1516, 2018.
, “Anthocyanins Protect SK-N-SH Cells Against Acrolein-Induced Toxicity by Preserving the Cellular Redox State.”, J Alzheimers Dis, vol. 50, no. 4, pp. 981-98, 2016.
, “Anthocyanins Protect SK-N-SH Cells Against Acrolein-Induced Toxicity by Preserving the Cellular Redox State.”, J Alzheimers Dis, vol. 50, no. 4, pp. 981-98, 2016.
, “Anthocyanins Protect SK-N-SH Cells Against Acrolein-Induced Toxicity by Preserving the Cellular Redox State.”, J Alzheimers Dis, vol. 50, no. 4, pp. 981-98, 2016.
, “The Anti-Amyloid Monoclonal Antibody Lecanemab: 16 Cautionary Notes.”, J Alzheimers Dis, vol. 94, no. 2, pp. 497-507, 2023.
, “The Anti-Amyloid Monoclonal Antibody Lecanemab: 16 Cautionary Notes.”, J Alzheimers Dis, vol. 94, no. 2, pp. 497-507, 2023.
, “The Anti-Amyloid Monoclonal Antibody Lecanemab: 16 Cautionary Notes.”, J Alzheimers Dis, vol. 94, no. 2, pp. 497-507, 2023.
, “The Anti-Amyloid Monoclonal Antibody Lecanemab: 16 Cautionary Notes.”, J Alzheimers Dis, vol. 94, no. 2, pp. 497-507, 2023.
, “Anti-amyloid β autoantibodies in cerebral amyloid angiopathy-related inflammation: implications for amyloid-modifying therapies.”, Ann Neurol, vol. 73, no. 4, pp. 449-58, 2013.
, “Anti-amyloid β autoantibodies in cerebral amyloid angiopathy-related inflammation: implications for amyloid-modifying therapies.”, Ann Neurol, vol. 73, no. 4, pp. 449-58, 2013.
, “Anti-amyloid β autoantibodies in cerebral amyloid angiopathy-related inflammation: implications for amyloid-modifying therapies.”, Ann Neurol, vol. 73, no. 4, pp. 449-58, 2013.
, “Anti-amyloid β autoantibodies in cerebral amyloid angiopathy-related inflammation: implications for amyloid-modifying therapies.”, Ann Neurol, vol. 73, no. 4, pp. 449-58, 2013.
,